Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

55.23 -0.91 (-1.62%)
Official Closing Price Updated: 7:00 PM EDT, Sep 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 15,505,114
Open 55.82
Bid (Size) 55.10 (1)
Ask (Size) 55.30 (3)
Prev. Close 56.14
Today's Range 54.73 - 56.08
52wk Range 45.05 - 138.22
Shares Outstanding N/A
Dividend Yield 3.98%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FDA Tightens Grip On Safe Weight Loss Drugs, WHO Adds Them To Essential Medicines List
FDA introduces a green list to block unsafe GLP-1 drug imports, while WHO updates its essential medicines list to include diabetes and cancer treatments. 
Via Benzinga
Faruqi & Faruqi Reminds Novo Nordisk Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 30, 2025 - NVO
From Faruqi & Faruqi LLP
Via GlobeNewswire

Performance

YTD
-36.9%
-36.9%
1 Month
+13.3%
+13.3%
3 Month
-26.8%
-26.8%
6 Month
-30.0%
-30.0%
1 Year
-57.9%
-57.9%

More News

Read More
Bragar Eagel & Squire, P.C. Reminds Investors of Novo, Altimmune, SelectQuote, and Spectrum that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Chinese Drugmakers Flooded US With Wegovy Copy Ingredients — Now They Are Pivoting To Generics: Report
Via Stocktwits
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
From The Rosen Law Firm PA
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
From Pomerantz LLP
Via GlobeNewswire
Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data
Via Benzinga
Levi & Korsinsky Notifies Shareholders of Novo Nordisk A/S (NVO) of a Class Action Lawsuit and an Upcoming Deadline
Via NewMediaWire
Topics Fraud Lawsuit
Levi & Korsinsky Notifies Shareholders of Novo Nordisk A/S (NVO) of a Class Action Lawsuit and an Upcoming Deadline
Via TheNewswire.com
Topics Fraud Lawsuit
Down 34%, Should You Buy the Dip on Viking Therapeutics?
Via The Motley Fool
Novo Nordisk A/S Class Action: Levi & Korsinsky Reminds Novo Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 30, 2025 - NVO
Via NewMediaWire
Topics Fraud Lawsuit
Novo Nordisk A/S Class Action: Levi & Korsinsky Reminds Novo Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 30, 2025 - NVO
Via TheNewswire.com
Topics Fraud Lawsuit
Where Will Eli Lilly Be in 3 Years?
Via The Motley Fool
Topics Intellectual Property
The Problem With Weight Loss Stocks
Via The Motley Fool
Topics Economy
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
From Faruqi & Faruqi LLP
Via GlobeNewswire
After Copycat Boom, China's Drugmakers Target Global Generics
Via Benzinga
Topics Supply Chain
Should You Buy Novo Nordisk Stock Now or Wait?
Via The Motley Fool
Shareholders That Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky About Pending Class Action - NVO
Via NewMediaWire
Topics Fraud Lawsuit
Shareholders That Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky About Pending Class Action - NVO
Via TheNewswire.com
Topics Fraud Lawsuit
Bragar Eagel & Squire, P.C. Reminds Investors of Novo, Altimmune, SelectQuote, and Spectrum that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Is Novo Nordisk Stock a Buy Now?
Via The Motley Fool
Marjorie Taylor Greene Hits Homerun Again, Buys Alphabet Stock 5 Days Before Favorable Antitrust Ruling: Here Are Some Other New Trades
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
From Pomerantz LLP
Via GlobeNewswire
NOVO NORDISK A/S (NYSE: NVO) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Novo Nordisk A/S Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire

Frequently Asked Questions

Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 55.23
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 09/05/25 07:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.